摘要
目的探讨消癌平注射液与埃克替尼联合对非小细胞肺癌晚期患者肿瘤局部控制率及血清鳞状细胞癌抗原（SCCA）、基质金属蛋白酶-9（MMP-9）、转化生长因子-β1（TGF-β1）水平变化的影响。方法选取非小细胞肺癌晚期患者60例，依据治疗方式不同分组，对照组30例予以埃克替尼治疗，研究组30例在对照组基础上联合消癌平注射液治疗，分析比较两组临床效果、血清SCCA、MMP-9、TGF-β1水平、不良反应及生存质量（WHOQOL-100）评分。
结果两组临床效果比较差异有统计学意义（P〈0.05），且研究组肿瘤局部控制率（83.33%）高于对照组（56.67%），差异有统计学意义（P〈0.05）；研究组治疗后2个月血清SCCA、MMP-9、TGF-β1水平低于对照组，差异有统计学意义（P〈0.05）；研究组不良反应发生率（6.67%）与对照组（3.33%）比较差异未见统计学意义（P〉0.05）；研究组治疗后2个月心理健康、生活能力、环境适应力、社会关系等WHOQOL-100评分高于对照组，差异有统计学意义（P〈0.05）。
结论非小细胞肺癌晚期患者予以消癌平注射液与埃克替尼联合治疗效果显著，可明显提高肿瘤局部控制率，降低其症状及血清SCCA、MMP-9、TGF-β1水平，提高预后，且具有安全性。
ObjectiveTo investigate the effect of icotinib combined with xiaoaiping injection on the local control rate and level changes of serum squamous cell carcinoma antigen （SCCA）, matrix metalloproteinase-9 （MMP-9） and transforming growth factor-β1 （TGF-β1） in patients with advanced non-small cell lung cancer.MethodsSixty cases of advanced non-small cell lung cancer were divided according to the different ways of treatment. Thirty cases in the control group were given icotinib, and 30 cases in the study group were given xiaoaiping injection based on the treatment in the control group. The clinical effects, levels of serum SCCA, MMP-9 and TGF-β1, adverse reactions and quality of life （WHOQOL-100） scores were analyzed and compared between the two groups.
ResultsThe clinical effects of the two groups were significantly different（P〈0.05）. The tumor local control rate of the study group was 83.33% （25/30）, which was higher than that of the control group [56.67% （17/30）], and the difference was significant（P〈0.05）. After the treatment for 2 months, the levels of serum SCCA, MMP-9 and TGF-β1 in the study group were lower than those in the control group, and the differences were significant（P〈0.05）. There was no significant difference in the incidence of adverse reactions between the study group [6.67% （2/30）] and the control group [3.33%（1/30）]（P〉0.05）. After 2 months of treatment, the WHOQOL-100 scores of mental health, living ability, environmental adaptability and social relationship of the study group were higher than those of the control group, and the differences were significant （P〈0.05）.
ConclusionsThe effect of icotinib combined with Shenyi capsules on patients with advanced NSCLC is significant. It can significantly improve the local control rate of tumor, reduce the symptoms and levels of serum SCCA, MMP-9 and TGF-β1, and improve the prognosis. Besides, it has high safety.
作者
高勇
C.ao Yong(Department of Chemotherapy I , Taian Tumor Prevention and Treatment Hospital, Taian 271000, China)
出处
《中国实用医刊》
2018年第6期110-113,共4页
Chinese Journal of Practical Medicine
